384 related articles for article (PubMed ID: 24874471)
1. Identification of druggable cancer driver genes amplified across TCGA datasets.
Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.
Ohshima K; Hatakeyama K; Nagashima T; Watanabe Y; Kanto K; Doi Y; Ide T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Serizawa M; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Sci Rep; 2017 Apr; 7(1):641. PubMed ID: 28377632
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
4. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.
Mita H; Toyota M; Aoki F; Akashi H; Maruyama R; Sasaki Y; Suzuki H; Idogawa M; Kashima L; Yanagihara K; Fujita M; Hosokawa M; Kusano M; Sabau SV; Tatsumi H; Imai K; Shinomura Y; Tokino T
BMC Cancer; 2009 Jun; 9():198. PubMed ID: 19545448
[TBL] [Abstract][Full Text] [Related]
5. A Novel Method for Identifying the Potential Cancer Driver Genes Based on Molecular Data Integration.
Zhang W; Wang SL
Biochem Genet; 2020 Feb; 58(1):16-39. PubMed ID: 31115714
[TBL] [Abstract][Full Text] [Related]
6. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning.
Zhou W; Zhao Z; Wang R; Han Y; Wang C; Yang F; Han Y; Liang H; Qi L; Wang C; Guo Z; Gu Y
Mol Oncol; 2017 Oct; 11(10):1459-1474. PubMed ID: 28719033
[TBL] [Abstract][Full Text] [Related]
7. OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers.
Wang T; Ruan S; Zhao X; Shi X; Teng H; Zhong J; You M; Xia K; Sun Z; Mao F
Nucleic Acids Res; 2021 Jan; 49(D1):D1289-D1301. PubMed ID: 33179738
[TBL] [Abstract][Full Text] [Related]
8. Oncogenes expand during evolution to withstand somatic amplification.
Wang X; Li X; Zhang L; Wong SH; Wang MHT; Tse G; Dai RZW; Nakatsu G; Coker OO; Chen Z; Ko H; Chan JYK; Liu T; Cheng CHK; Cheng ASL; To KF; Plewczynski D; Sung JJY; Yu J; Gin T; Chan MTV; Wu WKK
Ann Oncol; 2018 Nov; 29(11):2254-2260. PubMed ID: 30204835
[TBL] [Abstract][Full Text] [Related]
9. Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
Poulos RC; Wong YT; Ryan R; Pang H; Wong JWH
PLoS Genet; 2018 Nov; 14(11):e1007779. PubMed ID: 30412573
[TBL] [Abstract][Full Text] [Related]
10. High-resolution genomic and expression analyses of copy number alterations in breast tumors.
Haverty PM; Fridlyand J; Li L; Getz G; Beroukhim R; Lohr S; Wu TD; Cavet G; Zhang Z; Chant J
Genes Chromosomes Cancer; 2008 Jun; 47(6):530-42. PubMed ID: 18335499
[TBL] [Abstract][Full Text] [Related]
11. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.
Lehmann BD; Shaver TM; Johnson DB; Li Z; Gonzalez-Ericsson PI; Sánchez V; Shyr Y; Sanders ME; Pietenpol JA
Mol Cancer Res; 2019 Sep; 17(9):1842-1853. PubMed ID: 31186280
[TBL] [Abstract][Full Text] [Related]
12. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
[TBL] [Abstract][Full Text] [Related]
13. Altered oncomodules underlie chromatin regulatory factors driver mutations.
Frigola J; Iturbide A; Lopez-Bigas N; Peiro S; Gonzalez-Perez A
Oncotarget; 2016 May; 7(21):30748-59. PubMed ID: 27095575
[TBL] [Abstract][Full Text] [Related]
14. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.
Both J; Krijgsman O; Bras J; Schaap GR; Baas F; Ylstra B; Hulsebos TJ
PLoS One; 2014; 9(12):e115835. PubMed ID: 25551557
[TBL] [Abstract][Full Text] [Related]
15. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM
Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346
[TBL] [Abstract][Full Text] [Related]
16. SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors.
Newberg JY; Black MA; Jenkins NA; Copeland NG; Mann KM; Mann MB
Nucleic Acids Res; 2018 Sep; 46(16):e94. PubMed ID: 29846651
[TBL] [Abstract][Full Text] [Related]
17. Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework.
Yang H; Wei Q; Zhong X; Yang H; Li B
Bioinformatics; 2017 Feb; 33(4):483-490. PubMed ID: 27797769
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer driver copy number alterations identified by joint expression/CNA data analysis.
Wang G; Anastassiou D
Sci Rep; 2020 Oct; 10(1):17199. PubMed ID: 33057153
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.
Gnad F; Doll S; Manning G; Arnott D; Zhang Z
BMC Genomics; 2015; 16 Suppl 8(Suppl 8):S5. PubMed ID: 26110843
[TBL] [Abstract][Full Text] [Related]
20. Discovering potential cancer driver genes by an integrated network-based approach.
Shi K; Gao L; Wang B
Mol Biosyst; 2016 Aug; 12(9):2921-31. PubMed ID: 27426053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
